Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

Completed · Not applicable

Conditions studied: Sarcoma

In brief

To determine the percentage of patients and number of cycles in which a packed red blood cell transfusion was administered due to anemia and in which antibiotics were administered due to neutropenic fever.

Key facts

Study ID

NCT00283621

Run by

M.D. Anderson Cancer Center

People needed

51

Starts

2003-06-02

Expected to finish

2006-04-12

Last updated by the study team

2018-11-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with sarcoma which is locally advanced, at high risk for relapsed or metastatic for whom treatment with AI is indicated
• Must be between 18-65 years of age
• Women of childbearing potential should use effective contraceptive measures
• Adequate hematologic, renal, and hepatic functions
• Karnofsky performance status above or equal to 80

You may not qualify if…

• Pregnant or lactating women.
• Patients with comorbid condition which renders patients at high risk of treatment complication
• Patients with metastatic disease to CNS
• Patients with significant cardiac abnormalities
• History of seizure disorder in the past 5 years
• Patient has received any packed red blood cell transfusion within 2 weeks before study entry
• Prior surgery or radiation therapy within 2 weeks of study entry
• History of prior chemotherapy for sarcomas
• Iron deficiency
• Hypersensitivity to E.coli derived products

Where it is running

• UT MDAnderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.